80%+
Parkinson's · Lewy body
Sensitivity and specificity of blood NDE α-synuclein against the CSF seed-amplification assay, in 150 clinically diagnosed PD and LBD patients.
01 — The specificity problem
The brain expresses almost everything. Almost nothing is only the brain's.
A protein measured in whole plasma is a sum over every tissue that makes it. For the pathology that defines Parkinson's, ALS or Alzheimer's, that sum is noise. Isolating the neuron's own vesicles first restores the signal.
80%
of all human genes are expressed in the brain.
0.6%
are highly specific to the brain; a further 9% are brain-enriched. The remaining 90% cannot serve as biomarkers in whole blood.
>91%
of brain RNA and protein require neuron-derived vesicles to be detected in blood at all. That is what ExoSort isolates.
02 — The ExoSort platform
Immunoaffinity isolation of neuron-derived vesicles from a standard plasma tube.
ExoSort binds neuron-surface markers and pulls neuron-derived vesicles out of the total vesicle pool — leaving the body's noise behind and making disease-specific, non-brain-specific proteins readable for the first time in blood.
-
01
Plasma draw
Standard EDTA plasma, frozen. Retrospective biobank samples qualify.
-
02
Immunoaffinity capture
ExoSort binds neuron-surface markers and pulls NDEs from the total vesicle pool.
-
03
Cargo measurement
Immunoassay, RNA-seq, PCR or mass spectrometry — chosen for the question.
-
04
Qualified report
Documented CV, QC and traceability, formatted for your statisticians.
03 — The Neurodiagnostic panel
Eight biomarkers. One blood tube.
Each assay monitors biological response to treatment — pathway engagement, pharmacodynamics, treatment response — from the same draw. Panels are composed per program.
| Biomarker | Indications | Context of use | Status |
|---|---|---|---|
| α-Synuclein | Parkinson's, MSA, Lewy body, Alzheimer's | Pathway engagement · PD response · stratification vs CSF seeding | Qualified |
| TDP-43 | ALS, FTD, Alzheimer's | Pathway engagement · treatment response | Qualified |
| Tau / pTau | Alzheimer's disease | Pathway engagement · treatment response | Panel |
| NF-L | Brain injury, neuroinflammation | Neuronal damage · pharmacodynamics | Panel |
| LC3 | Autophagy / lysosome, cross-disease | Pathway engagement · treatment response | Panel |
| NF-κB | Neuroinflammation, cross-disease | Pathway engagement · treatment response | Panel |
| AKT panel | Metabolic signalling (e.g. GLP-1) | Pharmacodynamics · treatment response | Panel |
| Synaptic proteins | Synaptic plasticity, cross-disease | Pharmacodynamics · treatment response | Panel |
04 — Evidence
Qualified assays. Published cohorts.
<20%
ALS · FTD
Assay variability for the TDP-43 panel, qualified and deployed with more than seven pharmaceutical partners.
0.93
PPMI · RNA sequencing
Batch-to-batch reproducibility (R) across 1,100 PPMI samples at three time points, with TGen and The Michael J. Fox Foundation.
05 — Services
From discovery to Phase III, under one roof.
01
Biomarker discovery & validation
Unbiased discovery in neuron-enriched vesicles by immunoassay, proteomics and RNA sequencing.
02
Translational biomarkers
Translate an existing assay into an NDE blood biomarker and carry it into endpoints a program can act on.
03
NDE isolation & analysis
Custom isolation, quantification and characterisation, with downstream assay integration and reporting.
04
Clinical trial support
Stratification, pharmacodynamic monitoring and endpoint analysis across Phase I–III, multi-site and international.
Collaborators & funders
YaleStanfordJohns HopkinsMass GeneralNIHThe Michael J. Fox FoundationADDFTGenAlkermesQurAlisNeuroSenseSBH SciencesUniversity of Trieste
06 — Start a conversation
Tell us about your program.
A scientist — not a sales team — reads every request. Expect a scoped proposal with assay options, sample requirements and timelines within five working days.
NeuroDex Inc · 22 Strathmore Road, Natick, MA 01760